Roche forges deal with San Diego biotech, bet­ting on new an­tibi­ot­ic class

6 years ago
Deals

Oprah day in biotech: Re­ge­na­cy gets $30M, Ab­bisko gets $70M, Cas­tle Creek gets $75M

6 years ago
News Briefing

Covid-19 roundup: Bris­tol My­ers sus­pends clin­i­cal tri­als, grounds field team; Vir ush­ers an­ti­body can­di­dates to hu­man ...

6 years ago
Coronavirus

In two-way race with No­var­tis, Mer­ck scores first reg­u­la­to­ry ap­proval for tar­get­ed lung can­cer drug

6 years ago
R&D

FDA is­sues an­oth­er safe­ty alert re­lat­ed to fe­cal trans­plants, as da­ta sug­gest coro­n­avirus lingers in poop

6 years ago
FDA+
Coronavirus

BeiGene scram­bles to find new Abrax­ane sup­pli­er as Chi­nese in­spec­tors or­der halt on im­ports, cit­ing Bris­tol My­ers ...

6 years ago
China
FDA+

The first big hur­dle on the Cel­gene CVR ar­rives to­day. Can Bris­tol My­ers clear a low bar in the mid­dle of a pan­dem­ic?

6 years ago
FDA+

Mod­er­na CEO Stéphane Ban­cel out­lines a short path for emer­gency use of a coro­n­avirus vac­cine

6 years ago
Coronavirus

Kally­ope lands $112 mil­lion Se­ries C to ride the gut-brain ax­is for an­oth­er 3 years

6 years ago
Financing

Join­ing No­var­tis in siR­NA space, As­traZeneca hands Si­lence $80M up­front for dis­cov­ery deal

6 years ago
Deals
Discovery

Turn on, tune in: New York biotech scores $15M+ in chemo­ge­net­ics bet

6 years ago
Startups
Cell/Gene Tx

FDA opens door to emer­gency use of con­va­les­cent plas­ma from re­cov­ered Covid-19 pa­tients

6 years ago
Coronavirus

No­var­tis an­nounces pos­i­tive da­ta from halt­ed Zol­gens­ma tri­al

6 years ago
R&D

Covid-19 roundup: Where is Dr. Fau­ci?; AS­CO goes vir­tu­al

6 years ago
Coronavirus

How to build CAR–M: Carl June pro­tégé and his biotech pub­lish first ev­i­dence in Na­ture Biotech­nol­o­gy

6 years ago
People
Discovery

De­spite protests, Mile­stone Phar­ma gets clob­bered by a PhI­II crash in the clin­ic

6 years ago
R&D

BP­CIA turns 10: Near­ly 100 drugs be­come bi­o­log­ics

6 years ago
FDA+

Four years af­ter near-death ex­pe­ri­ence, PhI­II da­ta bring good news for No­vavax

6 years ago
R&D

'I have a feel­ing': Trump-en­dorsed malar­ia drug fails to pass muster in small Chi­nese coro­n­avirus study

6 years ago
Coronavirus

Astel­las em­pow­ers new­ly en­er­gized Cy­tomX with $80M up­front to get pre­clin­i­cal bis­pe­cif­ic work go­ing

6 years ago
Deals
Discovery

BEL­LUS Health buys IP rights, ban­ish­es roy­al­ties; Ab­b­Vie gets con­fir­ma­to­ry da­ta on ac­cel­er­at­ed AML drug

6 years ago
News Briefing

Bay­er inks up with “small” In­di­an biotech for new ap­proach at an old tar­get

6 years ago
Deals
R&D

Caught in a Covid-19 mael­strom, Eli Lil­ly locks down clin­i­cal tri­als as multi­bil­lion-dol­lar R&D ops de­rail

6 years ago
R&D
Coronavirus

Covid-19 roundup: FDA stamps quick OK on Roche's Actem­ra PhI­II; AlloVir ex­pands Bay­lor pact

6 years ago
Coronavirus
First page Previous page 850851852853854855856 Next page Last page
A service from the Financial Times